STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders,...

Full description

Bibliographic Details
Main Authors: Erickson, Craig A., Veenstra-Vanderweele, Jeremy M., Melmed, Raun D., McCracken, James T., Ginsberg, Lawrence D., Sikich, Linmarie, Scahill, Lawrence, Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Carpenter, Randall L., Wang, Paul P., King, Bryan H., Bear, Mark
Other Authors: Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Format: Article
Language:en_US
Published: Springer-Verlag 2015
Online Access:http://hdl.handle.net/1721.1/95779

Internet

http://hdl.handle.net/1721.1/95779

Similar Items